Is OSCR a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Membership growth and share gains, with revenue (ttm) at ~$13 billion. The bear case rests on the dominant risk is policy. Analysts covering it are spread from $13.00 to $36.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is policy. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $13.00, -58.2% from the $31.12 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Membership growth and share gains. Oscar grew to about 3.2 million members in early 2026, roughly 56% higher than a year earlier, expanding faster than the overall ACA marketplace. The most optimistic analyst target on OSCR is $36.00, +15.7% from the $31.12 price. That figure is only reachable if this thesis works close to its best case.

The dominant risk is policy. Oscar is a near pure-play ACA marketplace insurer, so the scheduled expiration of enhanced federal premium tax credits is an existential-level variable: if the credits are not extended, marketplace premiums could more than double for many enrollees, healthier members may drop coverage, and the remaining risk pool would skew sicker and more expensive. Oscar itself took a weighted-average rate increase near 28% for 2026 partly to account for worsening morbidity. Results are also highly seasonal and can be volatile, swinging from strong first-quarter profit to losses later in the year as the medical loss ratio climbs; full-year MLR is guided well above the Q1 figure. On top of that, Oscar competes against far larger, better-capitalized insurers, and any spike in medical costs, adverse regulatory change, or execution stumble hits a company still proving it can stay consistently profitable. The most pessimistic published target is $13.00, -58.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Oscar Health is a US health insurance company built around a digital-first member experience rather than the paperwork and call centers of legacy insurers.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Membership growth and share gains) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is policy) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a real turn to profitability, fast membership growth, and a technology platform that runs leaner than legacy insurers. The bear case is that Oscar is a near pure-play ACA insurer whose earnings hinge on federal subsidy policy, with volatile, seasonal results. Weigh both against your own portfolio.

Oscar Health is a US health insurance company that sells individual and family health plans, primarily through the Affordable Care Act marketplaces, with a digital-first member experience. Most of its revenue comes from insurance premiums. It also runs +Oscar, a technology platform it licenses to other healthcare organizations, plus brokerage and enrollment services.

The stock roughly doubled in 2026 after Oscar reported a record first quarter, with revenue up more than 50% year over year, net income near $679 million, and an improving medical loss ratio. Membership surged about 56%, and management reaffirmed full-year profit guidance. Optimism about a possible extension of ACA subsidies also lifted the shares on several occasions.